# About Medicine Tirzepatide — tirzepatide Research Digest

> Medicine Tirzepatide is an independent editorial project summarizing the peer-reviewed research literature on tirzepatide, the dual GIP/GLP-1 receptor agonist.

## What Medicine Tirzepatide is

Medicine Tirzepatide is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide — the dual GIP/GLP-1 receptor agonist studied across the SURPASS and SURMOUNT clinical programs. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The word "medicine" in the domain name reflects the framing of this project: a site positioned at the intersection of the published medical literature and general readability. It is an editorial designation — not a claim about clinical services offered here. There are no services offered here.

## What we publish

Every page on this site is a summary or digest of findings from the published, peer-reviewed literature. The primary sources are the SURPASS and SURMOUNT phase 3 trial programs, mechanistic studies published in JCI Insight, Cell Metabolism, Frontiers in Endocrinology, and CPT Pharmacometrics, and the FDA prescribing record for tirzepatide.

Every quantitative claim maps to a numbered citation in the References section. We do not write claims we cannot source to the published literature. We do not invent findings. If the data are uncertain, we say so.

## What we are not

We are not a clinic, a pharmacy, a prescriber, or a vendor. We do not dispense medical advice. We do not sell tirzepatide or any other compound. We do not provide consultation, treatment plans, or anything that could constitute clinical care.

Readers looking for clinical guidance on tirzepatide should consult a licensed physician or qualified healthcare provider.

## Editorial standards

1. Every quantitative claim cites a study from the peer-reviewed literature or the FDA prescribing record.
2. Dosing information is presented as documented in trial protocols — third person, study-attributed, never as a personal recommendation.
3. No competitor brand names appear on this site. Generic compound names are used throughout.
4. Adverse event data and safety findings receive the same editorial prominence as efficacy outcomes.

---

The tirzepatide clinical record — mechanism, trials, and pharmacokinetics — read from primary sources, cited numerically, and held by no clinic and no vendor.